JP2010505801A5 - - Google Patents

Download PDF

Info

Publication number
JP2010505801A5
JP2010505801A5 JP2009530916A JP2009530916A JP2010505801A5 JP 2010505801 A5 JP2010505801 A5 JP 2010505801A5 JP 2009530916 A JP2009530916 A JP 2009530916A JP 2009530916 A JP2009530916 A JP 2009530916A JP 2010505801 A5 JP2010505801 A5 JP 2010505801A5
Authority
JP
Japan
Prior art keywords
vaccine
serotype
den
vaccine composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009530916A
Other languages
English (en)
Japanese (ja)
Other versions
JP5269796B2 (ja
JP2010505801A (ja
Filing date
Publication date
Priority claimed from FR0608660A external-priority patent/FR2906724B1/fr
Application filed filed Critical
Publication of JP2010505801A publication Critical patent/JP2010505801A/ja
Publication of JP2010505801A5 publication Critical patent/JP2010505801A5/ja
Application granted granted Critical
Publication of JP5269796B2 publication Critical patent/JP5269796B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009530916A 2006-10-04 2007-10-02 4種のデング血清型に対する免疫付与の方法 Expired - Fee Related JP5269796B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0608660 2006-10-04
FR0608660A FR2906724B1 (fr) 2006-10-04 2006-10-04 Methode d'immunisation contre les 4 serotypes de la dengue.
PCT/FR2007/052054 WO2008047023A2 (fr) 2006-10-04 2007-10-02 Methode d'immunisation contre les 4 serotypes de la dengue

Publications (3)

Publication Number Publication Date
JP2010505801A JP2010505801A (ja) 2010-02-25
JP2010505801A5 true JP2010505801A5 (enExample) 2010-10-28
JP5269796B2 JP5269796B2 (ja) 2013-08-21

Family

ID=38222583

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009530916A Expired - Fee Related JP5269796B2 (ja) 2006-10-04 2007-10-02 4種のデング血清型に対する免疫付与の方法

Country Status (15)

Country Link
US (2) US7718358B2 (enExample)
EP (3) EP2526965A1 (enExample)
JP (1) JP5269796B2 (enExample)
KR (1) KR20090064593A (enExample)
CN (2) CN101553251B (enExample)
AR (1) AR063057A1 (enExample)
AU (1) AU2007311792B2 (enExample)
BR (1) BRPI0719849A2 (enExample)
CA (1) CA2663885A1 (enExample)
FR (1) FR2906724B1 (enExample)
IL (2) IL197768A0 (enExample)
MX (1) MX2009003417A (enExample)
TW (2) TWI406673B (enExample)
WO (1) WO2008047023A2 (enExample)
ZA (1) ZA200901816B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007021672A2 (en) * 2005-08-10 2007-02-22 Acambis Inc. Vaccination against dengue virus infection
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
CN105944095B (zh) 2008-03-05 2021-04-02 赛诺菲巴斯德有限公司 一种使含佐剂的疫苗组合物稳定的方法
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
WO2013188315A1 (en) * 2012-06-10 2013-12-19 Inviragen, Inc. Compositions and methods for administration of vaccines against dengue virus
CN102449172A (zh) * 2009-06-01 2012-05-09 伊维拉根公司 施用针对登革病毒的疫苗的组合物和方法
US8968996B2 (en) * 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
AU2010286368B2 (en) 2009-08-31 2015-09-03 Gen-Probe Incorporated Dengue virus assay
EP2353609A1 (en) * 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
US10238734B2 (en) 2010-03-23 2019-03-26 The Regents Of The University Of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
BR112013032421A2 (pt) * 2011-06-29 2017-01-17 Immunotope Inc método para profilaxia ou tratamento de uma infecção pelo vírus da dengue, método para induzir uma resposta imune mediada por linfócito t citotóxico, vacina contra o vírus da dengue, método para prevenir uma doença causada pelo vírus da dengue e método para induzir uma resposta imune a pelo menos um vírus da dengue
US8895028B2 (en) * 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
KR20150036592A (ko) * 2012-07-24 2015-04-07 사노피 파스퇴르 백신 조성물
US20150265695A1 (en) 2012-07-24 2015-09-24 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
EP2931310A4 (en) 2012-12-14 2016-05-25 Takeda Vaccines Inc COMPOSITIONS, METHODS OF ADMINISTRATION AND USES OF TRIVALENT FORMULATIONS AGAINST DENGUE VIRUS
EP3010536A4 (en) 2013-06-21 2016-11-30 Merck Sharp & Dohme DENGUE VIRUS VACCINE COMPOSITIONS AND METHODS FOR USE THEREOF
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
AU2015369875A1 (en) 2014-12-22 2017-06-15 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
US10655110B2 (en) * 2015-11-27 2020-05-19 Km Biologics Co., Ltd. Multivalent dengue vaccine composition comprising a mixture of attenuated dengue viruses from different serotypes
JP7313345B2 (ja) 2017-10-05 2023-07-24 サノフィ・パスツール デング熱に対するブースターワクチン接種のための組成物
US11590221B2 (en) 2018-09-05 2023-02-28 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
WO2021034349A1 (en) 2019-08-16 2021-02-25 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis a
US20240076631A2 (en) 2020-02-27 2024-03-07 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
WO2023147342A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2023158989A1 (en) 2022-02-15 2023-08-24 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
EP4519847A1 (en) 2022-05-04 2025-03-12 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
CN120225693A (zh) 2022-11-18 2025-06-27 武田疫苗股份有限公司 测定制剂中具有包含至少一个减毒基因座的核苷酸序列的活减毒黄病毒的比例的方法
EP4626574A1 (en) 2022-11-29 2025-10-08 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2025072259A1 (en) 2023-09-25 2025-04-03 Takeda Vaccines, Inc. Coadministration of tetravalent dengue vaccine with hpv vaccine
WO2025122855A1 (en) 2023-12-08 2025-06-12 Takeda Vaccines, Inc. A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040933A1 (en) 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
ES2345614T3 (es) 1997-02-28 2010-09-28 Sanofi Pasteur Biologics Co. Vacunas quimericas de flavivirus.
WO1999061916A1 (en) 1998-05-29 1999-12-02 Epimmune, Inc. Identification of broadly reactive dr restricted epitopes
WO2000057909A2 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-2 virus vaccine
US6537557B1 (en) * 1999-03-26 2003-03-25 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-4 virus vaccine
JP2002540169A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱1型ウイルスワクチン
JP2002540166A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱3型ウイルスワクチン
AU779280B2 (en) 1999-03-26 2005-01-13 Walter Reed Army Institute Of Research Multivalent dengue virus vaccine
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
DK2278012T3 (en) 2000-02-16 2015-12-07 Us Government Immunogenic dengue 2 virus chimeras
EP1159969A1 (fr) 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
DE60040652D1 (de) * 2000-05-30 2008-12-11 Univ Mahidol Attenuierte Stammen von Denguevirus und ihre Verwendungen in Impfstoffzusammensetzungen
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
CA2755964C (en) 2001-05-22 2017-06-27 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
WO2002095007A2 (en) 2001-05-23 2002-11-28 Dendreon San Diego Llc Conjugates activated by cell surface proteases and therapeutic uses thereof
EP1401859B1 (en) 2001-06-01 2013-08-07 Sanofi Pasteur Biologics Co. Chimeric flavivirus vectors
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
JP2005519639A (ja) * 2002-01-15 2005-07-07 アカンビス インコーポレーティッド フラビウイルスワクチン
AU2003239932A1 (en) * 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
ES2345200T3 (es) 2003-03-24 2010-09-17 The Scripps Research Institute Vacunas de adn contra el crecimiento tumoral y procedimientos de utilizacion de las mismas.
WO2006134433A1 (en) * 2005-06-17 2006-12-21 Sanofi Pasteur Dengue serotype 1 attenuated strain
WO2007021672A2 (en) * 2005-08-10 2007-02-22 Acambis Inc. Vaccination against dengue virus infection
FR2903605A1 (fr) 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue

Similar Documents

Publication Publication Date Title
JP2010511022A5 (enExample)
WO2008047023A3 (fr) Methode d'immunisation contre les 4 serotypes de la dengue
JP2015524421A5 (enExample)
JP2007302683A5 (enExample)
IL207468A (en) HCV inhibitors and their use in the preparation of medicines for the treatment of HCV infections
JP2013542224A5 (enExample)
WO2008022196A3 (en) Development of dengue virus vaccine components
WO2009080836A3 (en) Macrocyclic indoles as hepatitis c virus inhibitors
NO20090141L (no) Stabiliserte, farmasøytiske preparater som omfatter fesoterodin
JP2002540168A5 (enExample)
JP2009504654A5 (enExample)
WO2009106019A3 (es) Compuestos quimicos con accion antiviral contra virus dengue y otros flavivirus
MY184428A (en) Compositions and methods for administration of vaccines against dengue virus
WO2006083286A3 (en) Genetically engineered swine influenza virus and uses thereof
FI2313087T4 (fi) Farmaseuttinen annostelumuoto indolinoni-johdannaisen välittömään vapautumiseen
JP2016504315A5 (enExample)
FI3250182T3 (fi) Dispergoituvia koostumuksia
CA2915027A1 (en) Compositions and methods for administration of vaccines against dengue virus
PH12013501373B1 (en) Bovine viral diarrhea virus type 1b vaccine compositions and methods
ATE419006T1 (de) Multivalenter dengue-virus impfstoff
WO2007057763A3 (en) Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant
JP2009515987A5 (enExample)
JP2018502080A5 (enExample)
WO2002078631A3 (en) Improved conditionally replicating vectors for inhibiting viral infections
WO2013012835A3 (en) Sirna useful in the treatment of flavivirus infection